At the time of study design, the preliminary results of the early-phase study combining ibrutinib (420 mg daily) and R-CHOP were encouraging, particularly for patients with non-GC DLBCL [12]. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.